Off-label use of intravenous immunoglobulin for dermatological conditions a review of clinical effectiveness
This Rapid Response report aims to review the comparative effectiveness of intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) for off-label use for dermatological conditions, and is complementary to the 2017 CADTH Rapid Response, Summary of Abstracts report: "Off-Label Use...
Main Authors: | , |
---|---|
Corporate Author: | |
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, 2018
|
Series: | CADTH rapid response report: summary with critical appraisal
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | This Rapid Response report aims to review the comparative effectiveness of intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) for off-label use for dermatological conditions, and is complementary to the 2017 CADTH Rapid Response, Summary of Abstracts report: "Off-Label Use of Intravenous Immunoglobulin for Dermatological Conditions: Clinical Effectiveness" |
---|---|
Physical Description: | 1 PDF file (21 pages) illustrations |